Oruka Therapeutics, INC Form 4 insider transactions

Fairmount Funds Management converted 160 shares of Series A Preferred Stock into 160,000 shares of Oruka Therapeutics common stock following shareholder approval.

Fairmount Funds Management and related entities report acquisition of common stock and convertible preferred stock in Oruka Therapeutics through a private placement.

Jacob Ma-Weaver, formerly a director of ARCA biopharma, Inc., reports changes in beneficial ownership following the company's business combination on August 29, 2024, including the cancellation of incentive options and assignment of proceeds.

ARCA biopharma updates the special cash dividend amount to $1.613 per share in connection with its merger with Oruka Therapeutics, payable on August 28, 2024.

Janus Henderson Group PLC reports increased beneficial ownership in ARCA biopharma, Inc. through fund transactions.

ARCA biopharma declares a special cash dividend estimated at $1.59 per share in connection with its proposed merger with Oruka Therapeutics, pending stockholder approval.

ARCA Biopharma divests its legacy Gencaro and rNAPc2 assets to Genvara Biopharma for $300,000 as it progresses with its merger with Oruka Therapeutics.

ARCA Biopharma is set to merge with Oruka Therapeutics in a reverse-triangle merger, accompanied by a $275 million private investment in Oruka.

ARCA biopharma reported its second quarter 2024 financial results, highlighting cash reserves and ongoing strategic review, including a proposed merger with Oruka Therapeutics.

Janus Henderson Group PLC reports acquiring additional shares of ARCA biopharma, Inc., increasing its indirect beneficial ownership.

Janus Henderson Group PLC, through its fund, continues to increase its holdings in ARCA biopharma, Inc., with multiple purchases of common stock.

Oruka Therapeutics amends its subscription agreement with investors, issuing warrants to employees and service providers, in preparation for its merger with ARCA biopharma.

ARCA Biopharma is set to merge with Oruka Therapeutics, a company focused on developing best-in-class therapies for psoriasis and other inflammatory skin diseases, with a concurrent $275 million PIPE financing.

ARCA biopharma reported its first quarter 2024 financial results, announced a merger agreement with Oruka Therapeutics, and appointed Thomas Keuer as President.

ARCA biopharma and Oruka Therapeutics have announced a merger agreement to form a company focused on developing novel biologics for chronic skin diseases, supported by a $275 million pre-closing private financing.